VanEck Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $458M | Buy |
16,301,030
+2,958,270
| +22% | +$78.8M | 0.34% | 52 |
|
|
2025
Q4 | $332M | Sell |
13,342,760
-4,813,780
| -27% | -$121M | 0.27% | 77 |
|
|
2025
Q3 | $463M | Sell |
18,156,540
-4,744,499
| -21% | -$117M | 0.43% | 47 |
|
|
2025
Q2 | $555M | Buy |
22,901,039
+795,423
| +4% | +$18.6M | 0.63% | 32 |
|
|
2025
Q1 | $560M | Buy |
22,105,616
+818,811
| +4% | +$21.4M | 0.72% | 29 |
|
|
2024
Q4 | $565M | Buy |
21,286,805
+4,726,549
| +29% | +$128M | 0.72% | 31 |
|
|
2024
Q3 | $478M | Buy |
16,560,256
+456,168
| +3% | +$13.3M | 0.6% | 40 |
|
|
2024
Q2 | $451M | Buy |
16,104,088
+290,760
| +2% | +$8.01M | 0.64% | 32 |
|
|
2024
Q1 | $439M | Buy |
15,813,328
+2,829,178
| +22% | +$78.5M | 0.66% | 36 |
|
|
2023
Q4 | $374M | Buy |
12,984,150
+3,265,276
| +34% | +$98.7M | 0.68% | 44 |
|
|
2023
Q3 | $322M | Buy |
9,718,874
+2,273,275
| +31% | +$80.4M | 0.71% | 34 |
|
|
2023
Q2 | $273M | Buy |
7,445,599
+3,601,529
| +94% | +$140M | 0.6% | 46 |
|
|
2023
Q1 | $157M | Buy |
3,844,070
+2,326,950
| +153% | +$101M | 0.36% | 79 |
|
|
2022
Q4 | $77.7M | Buy |
1,517,120
+1,062
| +0.1% | +$50.9K | 0.2% | 120 |
|
|
2022
Q3 | $66.3M | Buy |
1,516,058
+207,989
| +16% | +$10.1M | 0.2% | 124 |
|
|
2022
Q2 | $68.6M | Buy |
1,308,069
+852,451
| +187% | +$43.4M | 0.18% | 128 |
|
|
2022
Q1 | $23.6M | Sell |
455,618
-31,474
| -6% | -$1.63M | 0.05% | 233 |
|
|
2021
Q4 | $28.8M | Sell |
487,092
-2,476,151
| -84% | -$123M | 0.07% | 218 |
|
|
2021
Q3 | $127M | Sell |
2,963,243
-1,878,344
| -39% | -$83.2M | 0.32% | 83 |
|
|
2021
Q2 | $190M | Buy |
4,841,587
+174,809
| +4% | +$6.8M | 0.45% | 52 |
|
|
2021
Q1 | $169M | Buy |
4,666,778
+1,251,532
| +37% | +$44.4M | 0.46% | 47 |
|
|
2020
Q4 | $126M | Sell |
3,415,246
-141,551
| -4% | -$5.19M | 0.37% | 60 |
|
|
2020
Q3 | $124M | Buy |
3,556,797
+186,546
| +6% | +$6.54M | 0.39% | 45 |
|
|
2020
Q2 | $105M | Buy |
3,370,251
+379,716
| +13% | +$12.9M | 0.36% | 44 |
|
|
2020
Q1 | $92.6M | Buy |
2,990,535
+92,856
| +3% | +$3.16M | 0.47% | 38 |
|
|
2019
Q4 | $108M | Buy |
2,897,679
+1,726,943
| +148% | +$61.5M | 0.42% | 42 |
|
|
2019
Q3 | $39.9M | Buy |
1,170,736
+230,020
| +24% | +$8.36M | 0.19% | 103 |
|
|
2019
Q2 | $38.7M | Buy |
940,716
+7,921
| +0.8% | +$315K | 0.19% | 115 |
|
|
2019
Q1 | $37.6M | Sell |
932,795
-75,233
| -7% | -$3.01M | 0.18% | 120 |
|
|
2018
Q4 | $41.7M | Sell |
1,008,028
-522,943
| -34% | -$21.7M | 0.21% | 94 |
|
|
2018
Q3 | $64M | Sell |
1,530,971
-51,246
| -3% | -$1.97M | 0.31% | 79 |
|
|
2018
Q2 | $54.5M | Buy |
1,582,217
+170,314
| +12% | +$5.82M | 0.25% | 92 |
|
|
2018
Q1 | $47.5M | Buy |
1,411,903
+40,261
| +3% | +$1.38M | 0.24% | 93 |
|
|
2017
Q4 | $47.1M | Sell |
1,371,642
-62,069
| -4% | -$2.12M | 0.23% | 97 |
|
|
2017
Q3 | $48.6M | Buy |
1,433,711
+484,905
| +51% | +$15.6M | 0.25% | 83 |
|
|
2017
Q2 | $30.2M | Buy |
948,806
+1,603
| +0.2% | +$50.6K | 0.17% | 114 |
|
|
2017
Q1 | $30.7M | Sell |
947,203
-20,801
| -2% | -$656K | 0.14% | 120 |
|
|
2016
Q4 | $29.8M | Buy |
968,004
+606,053
| +167% | +$18.5M | 0.15% | 109 |
|
|
2016
Q3 | $11.6M | Sell |
361,951
-32,915
| -8% | -$1.1M | 0.05% | 194 |
|
|
2016
Q2 | $13.2M | Sell |
394,866
-64,351
| -14% | -$2.05M | 0.07% | 177 |
|
|
2016
Q1 | $12.9M | Sell |
459,217
-182,324
| -28% | -$5.21M | 0.09% | 152 |
|
|
2015
Q4 | $19.6M | Buy |
641,541
+56,465
| +10% | +$1.78M | 0.16% | 131 |
|
|
2015
Q3 | $17.4M | Sell |
585,076
-69,937
| -11% | -$2.24M | 0.13% | 136 |
|
|
2015
Q2 | $20.8M | Sell |
655,013
-52,905
| -7% | -$1.72M | 0.12% | 144 |
|
|
2015
Q1 | $23.4M | Sell |
707,918
-10,278
| -1% | -$327K | 0.13% | 139 |
|
|
2014
Q4 | $21.2M | Sell |
718,196
-333,502
| -32% | -$9.56M | 0.13% | 134 |
|
|
2014
Q3 | $29.5M | Buy |
1,051,698
+154,999
| +17% | +$4.35M | 0.16% | 125 |
|
|
2014
Q2 | $25.3M | Buy |
896,699
+137,531
| +18% | +$3.92M | 0.12% | 133 |
|
|
2014
Q1 | $23.1M | Buy |
759,168
+121,959
| +19% | +$3.64M | 0.11% | 133 |
|
|
2013
Q4 | $18.5M | Buy |
637,209
+755
| +0.1% | +$22K | 0.09% | 141 |
|
|
2013
Q3 | $17.3M | Sell |
636,454
-174,832
| -22% | -$4.76M | 0.09% | 136 |
|
|
2013
Q2 | $21.6M | Buy |
+811,286
| New | +$22.4M | 0.12% | 101 |
|
Other funds holding PFE
VCM
VPM
VanEck Associates's PFE Position: Q1 2026 in Review
VanEck Associates increased its Pfizer (PFE) stake by 22% in Q1 2026, buying an estimated $78.8M and bringing the position to 16,301,030 shares worth $458M. The position accounts for 0.34% of the portfolio, ranked #52.
VanEck Associates first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $565M in Q4 2024. 2,949 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- VanEck Associates held 16,301,030 shares of Pfizer worth $458M as of Q1 2026.
- VanEck Associates bought 2,958,270 Pfizer shares in Q1 2026, an estimated $78.8M.
- Pfizer made up 0.34% of VanEck Associates's portfolio in Q1 2026, its #52 holding.
- VanEck Associates first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- VanEck Associates's Pfizer position peaked at $565M in Q4 2024.
- 2,949 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.